Updated Safety Data from a Randomized Phase 2 Trial of Hedgehog Pathway Inhibitor GDC-0449 vs. Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients.
Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF
No Effect on Tumor Response with Weekly Oxaliplatin Added to Standard Preoperative 5-FU/RT in locally Advanced Rectal Cancer Ali Shamsedddine, MD Professor.
Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the STAR.
Johanna Bendell, MD Director, GI Oncology Research Associate Director, Drug Development Unit
Ali Shamsedddine, MD Professor of Medicine Head of Hematology-Oncology Division
ABSTRACT
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
1 ODAC September 13 th, 2005 Tarceva ® (erlotinib) Adrian Senderowicz, M.D. DDODP, CDER FDA.
These slides were released by the speaker for internal use by Novartis
Adam M. Brufsky, MD, PhD
Presented by Celine BOUTROS Hotel- Dieu de France
